| Year |
Citation |
Score |
| 2020 |
Mátyási B, Farkas Z, Kopper L, Sebestyén A, Boissan M, Mehta A, Takács-Vellai K. The Function of NM23-H1/NME1 and Its Homologs in Major Processes Linked to Metastasis. Pathology Oncology Research : Por. PMID 31993913 DOI: 10.1007/S12253-020-00797-0 |
0.35 |
|
| 2018 |
Sticz T, Molnár A, Dankó T, Hujber Z, Petővári G, Nagy N, Végső G, Kopper L, Sebestyén A. The Effects of Different mTOR Inhibitors in EGFR Inhibitor Resistant Colon Carcinoma Cells. Pathology Oncology Research : Por. PMID 29882195 DOI: 10.1007/S12253-018-0434-4 |
0.395 |
|
| 2016 |
Sticz T, Molnár A, Márk Á, Hajdu M, Nagy N, Végső G, Micsik T, Kopper L, Sebestyén A. mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression. Journal of Clinical Pathology. PMID 27729429 DOI: 10.1136/Jclinpath-2016-203913 |
0.318 |
|
| 2015 |
Sebestyén A, Márk Á, Hajdu M, Nagy N, Molnár A, Végs? G, Barna G, Kopper L. Rapamycin can restore the negative regulatory function of transforming growth factor beta 1 in high grade lymphomas. Cytokine. 73: 219-24. PMID 25794661 DOI: 10.1016/J.Cyto.2015.02.024 |
0.654 |
|
| 2015 |
Sebestyén A, Nagy N, Márk Á, Molnár A, Dankó T, Hajdu M, Tóth M, Timár B, Csóka M, Kopper L. Abstract B47: mTOR C1/2 activities - related protein expression and its potential prognostic/therapeutic importance in certain lymphoid malignancies Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-B47 |
0.436 |
|
| 2014 |
Schwab R, Petak I, Kollar M, Pinter F, Varkondi E, Kohanka A, Barti-Juhasz H, Schönleber J, Brauswetter D, Kopper L, Urban L. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer (Amsterdam, Netherlands). 83: 109-11. PMID 24192513 DOI: 10.1016/J.Lungcan.2013.10.006 |
0.33 |
|
| 2013 |
Márk Ã, Hajdu M, Váradi Z, Sticz TB, Nagy N, Csomor J, Berczi L, Varga V, Csóka M, Kopper L, Sebestyén A. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study. Bmc Cancer. 13: 250. PMID 23693095 DOI: 10.1186/1471-2407-13-250 |
0.441 |
|
| 2013 |
Nemes K, Sebestyén A, Márk A, Hajdu M, Kenessey I, Sticz T, Nagy E, Barna G, Váradi Z, Kovács G, Kopper L, Csóka M. Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL). Plos One. 8: e59335. PMID 23573198 DOI: 10.1371/Journal.Pone.0059335 |
0.638 |
|
| 2012 |
Sebestyén A, Sticz TB, Márk A, Hajdu M, Timár B, Nemes K, Nagy N, Váradi Z, Kopper L. Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 25: 1623-8. PMID 22899290 DOI: 10.1038/Modpathol.2012.141 |
0.4 |
|
| 2012 |
Kopper L, Sebestyén A, Gallai M, Kovalszky I. Syndecan-1 - A new piece in B-cell puzzle. Pathology Oncology Research : Por. 3: 183-91. PMID 18470728 DOI: 10.1007/Bf02899919 |
0.403 |
|
| 2012 |
Mark A, Hajdu M, Sticz T, Varadi Z, Nagy N, Timar B, Csoka M, Kopper L, Sebestyen A. 798 Mammalian Target of Rapamycin (mTOR) Activity as a Potential Target in Human Diffuse Large B-cell Lymphomas and Hodgkin Lymphomas European Journal of Cancer. 48: S190. DOI: 10.1016/S0959-8049(12)71431-4 |
0.352 |
|
| 2011 |
Balla P, Moskovszky L, Sapi Z, Forsyth R, Knowles H, Athanasou NA, Szendroi M, Kopper L, Rajnai H, Pinter F, Petak I, Benassi MS, Picci P, Conti A, Krenacs T. Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone. Histopathology. 59: 376-89. PMID 22034878 DOI: 10.1111/J.1365-2559.2011.03948.X |
0.31 |
|
| 2011 |
Egervári G, Márk A, Hajdu M, Barna G, Sápi Z, Krenács T, Kopper L, Sebestyén A. Mitotic lymphoma cells are characterized by high expression of phosphorylated ribosomal S6 protein. Histochemistry and Cell Biology. 135: 409-17. PMID 21424608 DOI: 10.1007/S00418-011-0803-5 |
0.676 |
|
| 2011 |
Sticz TB, Mark A, Hajdu M, Timar B, Nemes K, Kopper L, Sebestyen A. Abstract 3163: Tissue-micro array based IHC analysis of mTOR activity in DLBCL Cancer Research. 71: 3163-3163. DOI: 10.1158/1538-7445.Am2011-3163 |
0.386 |
|
| 2010 |
Moskovszky L, Dezsö K, Athanasou N, Szendröi M, Kopper L, Kliskey K, Picci P, Sápi Z. Centrosome abnormalities in giant cell tumour of bone: possible association with chromosomal instability. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 23: 359-66. PMID 20062006 DOI: 10.1038/Modpathol.2009.134 |
0.306 |
|
| 2010 |
Hajdu M, Kopper L, Sebestyén A. Notch-regulation upon Dll4-stimulation of TGFb-induced apoptosis and gene expression in human B-cell non-Hodgkin lymphomas. Scandinavian Journal of Immunology. 71: 29-37. PMID 20017807 DOI: 10.1111/J.1365-3083.2009.02346.X |
0.5 |
|
| 2009 |
Moskovszky L, Szuhai K, Krenács T, Hogendoorn PC, Szendroi M, Benassi MS, Kopper L, Füle T, Sápi Z. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Genes, Chromosomes & Cancer. 48: 468-79. PMID 19242928 DOI: 10.1002/Gcc.20656 |
0.326 |
|
| 2009 |
Kohut E, Hajdu M, Gergely P, Gopcsa L, Kilián K, Pálóczi K, Kopper L, Sebestyén A. Expression of TGFbeta1 and its signaling components by peripheral lymphocytes in systemic lupus erythematosus. Pathology Oncology Research : Por. 15: 251-6. PMID 19020994 DOI: 10.1007/S12253-008-9119-8 |
0.323 |
|
| 2008 |
Stelkovics E, Korom I, Marczinovits I, Molnar J, Rasky K, Raso E, Ficsor L, Molnar B, Kopper L, Krenacs T. Collagen XVII/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy. Applied Immunohistochemistry & Molecular Morphology : Aimm / Official Publication of the Society For Applied Immunohistochemistry. 16: 433-41. PMID 18633319 DOI: 10.1097/Pai.0B013E318162F8Aa |
0.313 |
|
| 2008 |
Barna G, Reiniger L, Tátrai P, Kopper L, Matolcsy A. The cut-off levels of CD23 expression in the differential diagnosis of MCL and CLL. Hematological Oncology. 26: 167-70. PMID 18381689 DOI: 10.1002/Hon.855 |
0.577 |
|
| 2008 |
Nagy K, Barti-Juhász H, Árvai K, Schwab R, Peták I, Kopper L. A TRAIL (TNF-related-apoptosis inducing ligand) és bortezomib a vastagbélrák személyreszabott kezelésében Zeitschrift FüR Gastroenterologie. 46. DOI: 10.1055/S-2008-1079673 |
0.325 |
|
| 2007 |
Schwab R, Micsik T, Szokolóczi O, Schafer E, Tihanyi B, Tihanyi T, Kupcsulik P, Diófalvi K, Mersich T, Besznyak I, Zarand A, Mihalik R, Sarkadi B, Kéri G, Pap A, ... ... Kopper L, et al. Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors. Assay and Drug Development Technologies. 5: 541-50. PMID 17767422 DOI: 10.1089/Adt.2007.067 |
0.376 |
|
| 2007 |
Sebestyén A, Hajdu M, Kis L, Barna G, Kopper L. Smad4-independent, PP2A-dependent apoptotic effect of exogenous transforming growth factor beta 1 in lymphoma cells. Experimental Cell Research. 313: 3167-74. PMID 17643425 DOI: 10.1016/J.Yexcr.2007.05.028 |
0.719 |
|
| 2007 |
Papay J, Krenacs T, Moldvay J, Stelkovics E, Furak J, Molnar B, Kopper L. Immunophenotypic profiling of nonsmall cell lung cancer progression using the tissue microarray approach. Applied Immunohistochemistry & Molecular Morphology : Aimm / Official Publication of the Society For Applied Immunohistochemistry. 15: 19-30. PMID 17536303 DOI: 10.1097/01.Pai.0000213143.32030.F5 |
0.417 |
|
| 2007 |
Végso G, Sebestyén A, Paku S, Barna G, Hajdu M, Tóth M, Járay J, Kopper L. Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. Leukemia Research. 31: 1003-8. PMID 17320952 DOI: 10.1016/J.Leukres.2006.12.019 |
0.691 |
|
| 2007 |
Hajdu M, Sebestyén A, Barna G, Reiniger L, Jánosi J, Sréter L, Várkonyi J, Demeter J, Kopper L. Activity of the notch-signalling pathway in circulating human chronic lymphocytic leukaemia cells. Scandinavian Journal of Immunology. 65: 271-5. PMID 17309782 DOI: 10.1111/J.1365-3083.2006.01897.X |
0.648 |
|
| 2007 |
Sebestyén A, Hajdu M, Barna G, Kopper L. 381 POSTER Rapamycin potentiates the apoptotic effect of TGFb in lymphoma cells European Journal of Cancer Supplements. 5: 79. DOI: 10.1016/S1359-6349(07)70399-3 |
0.657 |
|
| 2006 |
Nagy K, Székely-Szüts K, Izeradjene K, Douglas L, Tillman M, Barti-Juhász H, Dominici M, Spano C, Luca Cervo G, Conte P, Houghton JA, Mihalik R, Kopper L, Peták I. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. Pathology Oncology Research : Por. 12: 133-42. PMID 16998592 DOI: 10.1007/Bf02893359 |
0.651 |
|
| 2006 |
Reiniger L, Bödör C, Bognár A, Balogh Z, Csomor J, Szepesi A, Kopper L, Matolcsy A. Richter's and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation. Leukemia. 20: 1089-95. PMID 16541139 DOI: 10.1038/Sj.Leu.2404183 |
0.351 |
|
| 2006 |
Petak I, Houghton J, Kopper L. Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer Current Signal Transduction Therapy. 1: 113-131. DOI: 10.2174/157436206775269217 |
0.341 |
|
| 2005 |
Barna G, Sebestyén A, Weischede S, Peták I, Mihalik R, Formelli F, Kopper L. Different ways to induce apoptosis by fenretinide and all-trans-retinoic acid in human B lymphoma cells. Anticancer Research. 25: 4179-85. PMID 16309214 |
0.673 |
|
| 2005 |
Nagy K, Petak I, Imre G, Barna G, Gezane-Csorba M, Sebestyen A, Houghton JA, Mihalik R, Kopper L. Proteasome inhibitors abolish cell death downstream of caspase activation during anti-microtubule drug-induced apoptosis in leukemia cells. Anticancer Research. 25: 3321-6. PMID 16101145 |
0.717 |
|
| 2005 |
Bognár A, Csernus B, Bödör C, Reiniger L, Szepesi A, Tóth E, Kopper L, Matolcsy A. Clonal selection in the bone marrow involvement of follicular lymphoma. Leukemia. 19: 1656-62. PMID 15973453 DOI: 10.1038/Sj.Leu.2403844 |
0.359 |
|
| 2005 |
Sebestyén A, Barna G, Nagy K, Jánosi J, Paku S, Kohut E, Berczi L, Mihalik R, Kopper L. Smad signal and TGFbeta induced apoptosis in human lymphoma cells. Cytokine. 30: 228-35. PMID 15927846 DOI: 10.1016/J.Cyto.2005.01.013 |
0.744 |
|
| 2005 |
Bödör C, Bognár A, Reiniger L, Szepesi A, Tóth E, Kopper L, Matolcsy A. Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma. British Journal of Haematology. 129: 373-6. PMID 15842661 DOI: 10.1111/J.1365-2141.2005.05454.X |
0.346 |
|
| 2005 |
Mihalik R, Imre G, Petak I, Szende B, Kopper L. Cathepsin B-independent abrogation of cell death by CA-074-OMe upstream of lysosomal breakdown. Cell Death and Differentiation. 11: 1357-60. PMID 15297886 DOI: 10.1038/Sj.Cdd.4401493 |
0.336 |
|
| 2004 |
Jánosi J, Sebestyén A, Bocsi J, Barna G, Nagy K, Vályi-Nagy I, Kopper L. [Mevastatin induced apoptosis in U266 human myeloma cell line]. Magyar Onkologia. 48: 333-7. PMID 15655579 |
0.741 |
|
| 2004 |
Csernus B, Timár B, Fülöp Z, Bognár A, Szepesi A, László T, Jáksó P, Warnke R, Kopper L, Matolcsy A. Mutational analysis of IgVH and BCL-6 genes suggests thymic B-cells origin of mediastinal (thymic) B-cell lymphoma. Leukemia & Lymphoma. 45: 2105-10. PMID 15370257 DOI: 10.1080/1042819042000219467 |
0.392 |
|
| 2004 |
Jánosi J, Sebestyén A, Bocsi J, Barna G, Nagy K, Vályi-Nagy I, Kopper L. Mevastatin-induced apoptosis and growth suppression in U266 myeloma cells. Anticancer Research. 24: 1817-22. PMID 15274361 |
0.74 |
|
| 2004 |
Szende B, Farid P, Végso G, Perner F, Kopper L. Apoptosis and P53, Bcl-2 and Bax gene expression in parathyroid glands of patients with hyperparathyroidism. Pathology Oncology Research : Por. 10: 98-103. PMID 15188026 DOI: 10.1007/Bf02893463 |
0.417 |
|
| 2004 |
Paku S, Nagy P, Kopper L, Thorgeirsson SS. 2-acetylaminofluorene dose-dependent differentiation of rat oval cells into hepatocytes: confocal and electron microscopic studies. Hepatology (Baltimore, Md.). 39: 1353-61. PMID 15122764 DOI: 10.1002/Hep.20178 |
0.346 |
|
| 2003 |
Paku S, Tóvári J, Lörincz Z, Timár F, Döme B, Kopper L, Raz A, Tímár J. Adhesion dynamics and cytoskeletal structure of gliding human fibrosarcoma cells: a hypothetical model of cell migration. Experimental Cell Research. 290: 246-53. PMID 14567984 DOI: 10.1016/S0014-4827(03)00334-3 |
0.363 |
|
| 2003 |
Petak I, Danam RP, Tillman DM, Vernes R, Howell SR, Berczi L, Kopper L, Brent TP, Houghton JA. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death and Differentiation. 10: 211-7. PMID 12700649 DOI: 10.1038/Sj.Cdd.4401132 |
0.358 |
|
| 2003 |
Krenacs L, Smyth MJ, Bagdi E, Krenacs T, Kopper L, Rudiger T, Zettl A, Muller-Hermelink HK, Jaffe ES, Raffeld M. The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. Blood. 101: 3590-3. PMID 12506019 DOI: 10.1182/Blood-2002-09-2908 |
0.354 |
|
| 2002 |
Barna G, Sebestyén A, Chinopoulos CC, Nagy K, Mihalik R, Paku S, Kopper L. TGF beta 1 kills lymphoma cells using mitochondrial apoptotic pathway with the help of caspase-8. Anticancer Research. 22: 3867-72. PMID 12553006 |
0.733 |
|
| 2002 |
Tímár J, Lapis K, Dudás J, Sebestyén A, Kopper L, Kovalszky I. Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Seminars in Cancer Biology. 12: 173-86. PMID 12083848 DOI: 10.1016/S1044-579X(02)00021-4 |
0.36 |
|
| 2002 |
Tímár J, Csuka O, Orosz Z, Jeney A, Kopper L. Molecular pathology of tumor metastasis. I. Predictive pathology. Pathology Oncology Research : Por. 7: 217-30. PMID 11692150 DOI: 10.1007/Bf03032353 |
0.302 |
|
| 2001 |
Tótth A, Sebestyén A, Barna G, Nagy K, Göndör A, Bocsi J, Mihalik R, Peták I, Houghton J, Kopper L. TGF beta 1 induces caspase-dependent but death-receptor independent apoptosis in lymphoid cells. Anticancer Research. 21: 1207-12. PMID 11396165 |
0.739 |
|
| 2001 |
Sebestyen A, Barna G, Gondor A, Nagy K, Weishede S, Bauer P, Kopper L. The apoptotic effect of TGF-beta in human lymphoma cells European Journal of Cancer. 37: S123. DOI: 10.1016/S0959-8049(01)80941-2 |
0.654 |
|
| 2000 |
Sebestyén A, Tótth A, Mihalik R, Szakács O, Paku S, Kopper L. Syndecan-1-dependent homotypic cell adhesion in HT58 lymphoma cells. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 21: 349-57. PMID 11006575 DOI: 10.1159/000030140 |
0.402 |
|
| 2000 |
Kopper L, Sebestyén A. Syndecans and the lymphoid system. Leukemia & Lymphoma. 38: 271-81. PMID 10830734 DOI: 10.3109/10428190009087018 |
0.415 |
|
| 1999 |
Mihalik R, Bauer P, Peták I, Krajcsi P, Marton A, Kun E, Kopper L. Interaction of cytocidal drugs and the inhibition of caspase-3 by 3-nitrosobenzamide. International Journal of Cancer. Journal International Du Cancer. 82: 875-9. PMID 10446456 DOI: 10.1002/(Sici)1097-0215(19990909)82:6<875::Aid-Ijc17>3.0.Co;2-T |
0.436 |
|
| 1999 |
Sebestyén A, Berczi L, Mihalik R, Paku S, Matolcsy A, Kopper L. Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas. British Journal of Haematology. 104: 412-9. PMID 10050727 DOI: 10.1046/J.1365-2141.1999.01211.X |
0.383 |
|
| 1999 |
Mihalik R, Sebestyén A, Barna G, Bauer P, Kopper L. Death receptors in etoposide treated lymphoma cells European Journal of Cancer. 35: S104. DOI: 10.1016/S0959-8049(99)80798-9 |
0.649 |
|
| 1998 |
Kovalszky I, Dudás J, Oláh-Nagy J, Pogány G, Töváry J, Timár J, Kopper L, Jeney A, Iozzo RV. Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. Molecular and Cellular Biochemistry. 183: 11-23. PMID 9655174 DOI: 10.1023/A:1006898920637 |
0.308 |
|
| 1998 |
Sebestyén A, Kovalszky I, Mihalik R, Gallai M, Bocsi J, László E, Benedek S, Sréter L, Kopper L. Expression of syndecan-1 in human B cell chronic lymphocytic leukaemia. European Journal of Cancer (Oxford, England : 1990). 33: 2273-7. PMID 9470818 DOI: 10.1016/S0959-8049(97)00248-7 |
0.404 |
|
| 1997 |
Mihalik R, Uher F, Peták, Sebestyén A, Kopper L. Regulation of Differentiation, Proliferation and Drug-Induced Apoptosis in HT58 Lymphoma Cells. Pathology Oncology Research : Por. 3: 100-105. PMID 11173634 DOI: 10.1007/Bf02907802 |
0.308 |
|
| 1996 |
Tótth Á, Schnur J, Ladányi A, Kopper L. Intracerebral Human Lymphoma - An Experimental Model. Pathology Oncology Research : Por. 2: 174-176. PMID 11173602 DOI: 10.1007/Bf02903522 |
0.4 |
|
| 1996 |
Mihalik R, Uher F, Pocsik É, Berczi L, Benczur M, Kopper L. Detection of Drug-induced Apoptosis by Flow Cytometry after Alkaline Extraction of Ethanol Fixed Cells. Pathology Oncology Research : Por. 2: 78-83. PMID 11173591 DOI: 10.1007/Bf02893956 |
0.406 |
|
| 1996 |
Mihalik R, Kopper L, Benczúr M. Modulation of drug-induced apoptosis in a human B-lymphoma cell line (HT58). Immunology Letters. 48: 17-21. PMID 8847085 DOI: 10.1016/0165-2478(95)02434-4 |
0.474 |
|
| 1996 |
Mihalik R, Farkas G, Kopper L, Benczúr M, Faragó A. Possible involvement of protein kinase C-epsilon in phorbol ester-induced growth inhibition of human lymphoblastic cells. The International Journal of Biochemistry & Cell Biology. 28: 925-33. PMID 8811841 DOI: 10.1016/1357-2725(96)00020-9 |
0.418 |
|
| 1996 |
Csáki C, Ferencz T, Sipos G, Kopper L, Schuler D, Borsi JD. Diffuse plasmacytosis in a child with brainstem glioma following multiagent chemotherapy and intensive growth factor support. Medical and Pediatric Oncology. 26: 367-71. PMID 8614371 DOI: 10.1002/(Sici)1096-911X(199605)26:5<367::Aid-Mpo10>3.0.Co;2-A |
0.317 |
|
| 1995 |
Timár J, Jeney A, Kovalszky, Kopper L. Role of Proteoglycans in Tumor Progression. Pathology Oncology Research : Por. 1: 85-93. PMID 11173574 DOI: 10.1007/Bf02893590 |
0.341 |
|
| 1995 |
Tímár J, Diczházi C, Bartha I, Pogány G, Paku S, Rásó E, Tóvári J, Ladányi A, Lapis K, Kopper L. Modulation of heparan-sulphate/chondroitin-sulphate ratio by glycosaminoglycan biosynthesis inhibitors affects liver metastatic potential of tumor cells. International Journal of Cancer. 62: 755-61. PMID 7558426 DOI: 10.1002/Ijc.2910620618 |
0.366 |
|
| 1991 |
Nagy P, Török N, Ladånyi A, Kopper L. Expression of transforming growth factor-beta 1 in human non-Hodgkin's lymphoma xenografts. Journal of the National Cancer Institute. 83: 1174-5. PMID 1886149 DOI: 10.1093/Jnci/83.16.1174 |
0.33 |
|
| 1990 |
Kopper L, Bankfalvi A, Mihalik R, Glant TT, Timar J. Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts Cancer Immunology, Immunotherapy. 32: 137-142. PMID 2289206 DOI: 10.1007/Bf01754211 |
0.334 |
|
| 1990 |
Timár J, Kovalszky I, Bánkfalvi A, Kopper L. Ultrastructural localization and internalization of proteoglycan epitopes in a human non-Hodgkin (B) lymphoma. Histochemistry. 94: 419-25. PMID 1699917 DOI: 10.1007/Bf00266450 |
0.376 |
|
| 1987 |
Rajnay J, Kopper L, Lapis K. Chemotherapeutic response of squamous cell carcinoma xenografts (subcutaneous and subrenal capsule assay). Oncology. 44: 307-11. PMID 3670798 DOI: 10.1159/000226500 |
0.323 |
|
| 1987 |
Timár J, Móczar E, Timár F, Pál K, Kopper L, Lapis K, Jeney A. Comparative study on Lewis lung tumor lines with 'low' and 'high' metastatic capacity. II. Cytochemical and biochemical evidence for differences in glycosaminoglycans. Clinical & Experimental Metastasis. 5: 79-87. PMID 3103961 DOI: 10.1007/Bf00116628 |
0.362 |
|
| 1987 |
Timar J, Kopper L, Pogany G, Jeney A, Lapis K. Effect of an anti-GAG agent KL-103 on tumour cell membranes and microinvasiveness European Journal of Cancer and Clinical Oncology. 23: 1805. DOI: 10.1016/0277-5379(87)90741-3 |
0.32 |
|
| 1987 |
Lapis K, Timár J, Pál K, Kopper L, Jeney A. Phenotype of metastatic cells as target for anti-metastatic interventions European Journal of Cancer and Clinical Oncology. 23: 1773. DOI: 10.1016/0277-5379(87)90627-4 |
0.317 |
|
| 1985 |
Lapis P, Kopper L, Bodrogi I, Sugár J, Lapis K, Eckhardt S. Characteristics and chemotherapeutic sensitivity of a human testicular cancer grown in artificially immunosuppressed mice. Oncology. 42: 112-8. PMID 2581199 DOI: 10.1159/000226012 |
0.361 |
|
| 1985 |
Lapis K, Timár J, Timár F, Pál K, Móczár E, Kopper L, Jeney A. Cell membrane alterations in highly metastatic tumour cells European Journal of Cancer and Clinical Oncology. 21: 1398. DOI: 10.1016/0277-5379(85)90417-1 |
0.365 |
|
| 1984 |
Kopper L, Magyarosy E, Nagy P, Lapis K, Számel I, Eckhardt S, Csata S, Wabrosch G, Répássy D. Renal cell carcinoma--xenotransplantation into immuno-suppressed mice. Oncology. 41: 19-24. PMID 6700931 DOI: 10.1159/000225784 |
0.322 |
|
| 1984 |
Kopper L, Magyarosy E, Jeney A, Lapis K, Szabolcs A, Otvös L. Potentiation of the antitumor action of 5-fluorouracil with 5-ethyl-2'-deoxyuridine in human colorectal tumor xenografts. Oncology. 41: 155-8. PMID 6328393 DOI: 10.1159/000225813 |
0.306 |
|
| 1983 |
Timár J, Kopper L, Pál K, Lapis K. Transmission and scanning-electronmicroscopy of experimental liver metastases derived from intrasplenically growing primary tumor. Pathology, Research and Practice. 177: 47-59. PMID 6622294 DOI: 10.1016/S0344-0338(83)80043-0 |
0.359 |
|
| 1981 |
Kopper L, Van Hanh T, Hegedüs C, Lapis K. Growth of human colorectal tumor xenografts in immunosuppressed mice reconstituted with normal cells. Experimental Cell Biology. 49: 141-7. PMID 6972884 DOI: 10.1159/000163816 |
0.308 |
|
| 1978 |
Kopper L, Jeney A, Lapis K, Török M. Studies of the growth of an ascitic tumour. II. A system to study the tumour-age dependent effect of antitumour agents. European Journal of Cancer. 14: 75-82. PMID 624305 DOI: 10.1016/0014-2964(78)90140-8 |
0.301 |
|
| 1978 |
Kopper L, Jeney A, Takács J, Benedeczky I, Dzurillay E, Lapis K. Studies of the growth of an ascitic tumour. I. Cellular and subcellular changes during the tumour growth. European Journal of Cancer. 14: 59-73. PMID 624304 DOI: 10.1016/0014-2964(78)90139-1 |
0.343 |
|
| 1976 |
Kopper L, Jeney A, Ferencz G, Lapis K, Szende B. Studies on in vitro carcinogenesis. I. Autoradiographic and biochemical study on the incorporation of labelled methylcholantrene into mouse embryonic cells. Zeitschrift Fur Krebsforschung Und Klinische Onkologie. Cancer Research and Clinical Oncology. 85: 117-24. PMID 130740 DOI: 10.1007/Bf00304944 |
0.312 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2006 |
Kopper L, Tímár J. Genomics of renal cell cancer-- does it provide breakthrough? Pathology Oncology Research : Por. 12: 5-11. PMID 16554910 DOI: 10.1007/Bf02893425 |
0.298 |
|
| 2011 |
Sebestven A, Nemes K, Mark A, Váradi Z, Hajdu M, Sticz T, Kopper L, Kovács G, Csoka M. 9205 ORAL Mammalian Target of Rapamycin (mTOR) Activity Dependent Protein Expression and Rapamycin Sensitivity in Pediatric Acute Lymphoblastic Leukemias European Journal of Cancer. 47: S641. DOI: 10.1016/S0959-8049(11)72470-4 |
0.297 |
|
| 2010 |
Kopper L. Panitumumab: an arrow on target. Pathology Oncology Research : Por. 16: 143-8. PMID 20432075 DOI: 10.1007/S12253-010-9257-7 |
0.297 |
|
| 1985 |
Pál K, Timár J, Kopper L, Lapis K. Immunological differences between high and low metastatic Lewis lung tumour (LLT) cells European Journal of Cancer and Clinical Oncology. 21: 1406. DOI: 10.1016/0277-5379(85)90441-9 |
0.295 |
|
| 2005 |
Paku S, Dezso K, Kopper L, Nagy P. Immunohistochemical analysis of cytokeratin 7 expression in resting and proliferating biliary structures of rat liver. Hepatology (Baltimore, Md.). 42: 863-70. PMID 16175606 DOI: 10.1002/Hep.20858 |
0.293 |
|
| 2005 |
Paku S, Kopper L, Nagy P. Development of the vasculature in "pushing-type" liver metastases of an experimental colorectal cancer. International Journal of Cancer. 115: 893-902. PMID 15729725 DOI: 10.1002/Ijc.20886 |
0.291 |
|
| 2003 |
Tímár J, Ladányi A, Peták I, Jeney A, Kopper L. Molecular pathology of tumor metastasis III. Target array and combinatorial therapies. Pathology Oncology Research : Por. 9: 49-72. PMID 12704448 DOI: 10.1007/Bf03033715 |
0.289 |
|
| 2005 |
Kopper L, Tímár J. Genomics of lung cancer may change diagnosis, prognosis and therapy. Pathology Oncology Research : Por. 11: 5-10. PMID 15800676 DOI: 10.1007/Bf03032399 |
0.288 |
|
| 2008 |
Pinter F, Papay J, Almasi A, Sapi Z, Szabo E, Kanya M, Tamasi A, Jori B, Varkondi E, Moldvay J, Szondy K, Keri G, Dominici M, Conte P, Eckhardt S, ... Kopper L, et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. The Journal of Molecular Diagnostics : Jmd. 10: 160-8. PMID 18258923 DOI: 10.2353/Jmoldx.2008.070125 |
0.284 |
|
| 1990 |
Kopper L, Bánkfalvi A, Földi J, Mihalik R, Magyar M, Aczél A. Bigenotypic and biphenotypic appearance of immunoglobulin light chains in 1 of 3 non-Hodgkin's lymphoma xenografts. Oncology. 47: 393-7. PMID 2120650 DOI: 10.1159/000226855 |
0.28 |
|
| 1999 |
Timar J, Raso E, Paku S, Kopper L. Oral administration of a trace element preparation and zinc inhibit liver metastasis of 3LL-HH murine tumor cells. International Journal of Molecular Medicine. 2: 105-8. PMID 9854152 DOI: 10.3892/Ijmm.2.1.105 |
0.28 |
|
| 2010 |
Mark A, Hajdu M, Nemes K, Sticz T, Krenács T, Kopper L, Sebestyén A. 559 Galectin-1 expression in Hodgkin-lymphoma cells European Journal of Cancer Supplements. 8: 142-143. DOI: 10.1016/S1359-6349(10)71360-4 |
0.278 |
|
| 2010 |
Peták I, Schwab R, Orfi L, Kopper L, Kéri G. Integrating molecular diagnostics into anticancer drug discovery. Nature Reviews. Drug Discovery. 9: 523-35. PMID 20531274 DOI: 10.1038/Nrd3135 |
0.276 |
|
| 2016 |
Krencz I, Sebestyén A, Fábián K, Márk Á, Moldvay J, Khoor A, Kopper L, Pápay J. Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma. Human Pathology. PMID 28025080 DOI: 10.1016/J.Humpath.2016.12.012 |
0.276 |
|
| 1986 |
Pál K, Kopper L, Lapis K. Chemotherapeutic sensitivity of liver metastases from intrasplenically-growing Lewis lung tumor. Clinical & Experimental Metastasis. 1: 341-7. PMID 6443744 DOI: 10.1007/Bf00121196 |
0.276 |
|
| 1994 |
Bauer PI, Farkas G, Mihalik R, Kopper L, Kun E, Faragó A. Phosphorylation of poly(ADP-ribose)polymerase protein in human peripheral lymphocytes stimulated with phytohemagglutinin. Biochimica Et Biophysica Acta. 1223: 234-9. PMID 8086493 DOI: 10.1016/0167-4889(94)90231-3 |
0.273 |
|
| 1980 |
Kopper L, Van Hanh T, Lapis K, Timár J. Increased take rate of human tumour xenografts after carragheenan treatment. European Journal of Cancer. 16: 671-8. PMID 7389793 DOI: 10.1016/0014-2964(80)90208-X |
0.272 |
|
| 2002 |
Tímár J, Csuka O, Orosz Z, Jeney A, Kopper L. Molecular pathology of tumor metastasis. II. Molecular staging and differential diagnosis. Pathology Oncology Research : Por. 8: 204-19. PMID 12516003 DOI: 10.1007/Bf03032397 |
0.271 |
|
| 1986 |
Jeney A, Kopper L, Nagy P, Lapis K, Süli-Vargha H, Medzihradszky K. Antitumor action of N-(2-chloroethyl)-N-nitrosocarbamoyl derivatives of biologically active polypeptide hormone fragments. Cancer Chemotherapy and Pharmacology. 16: 129-32. PMID 3948298 DOI: 10.1007/Bf00256162 |
0.268 |
|
| 2004 |
Timár B, Fülöp Z, Csernus B, Angster C, Bognár A, Szepesi A, Kopper L, Matolcsy A. Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome. Leukemia. 18: 326-30. PMID 14671632 DOI: 10.1038/Sj.Leu.2403249 |
0.268 |
|
| 2005 |
Kopper L, Tímár J. Genomics of prostate cancer: is there anything to "translate"? Pathology Oncology Research : Por. 11: 197-203. PMID 16388315 DOI: 10.1007/Bf02893851 |
0.267 |
|
| 2008 |
Kopper L. Lapatinib: a sword with two edges. Pathology Oncology Research : Por. 14: 1-8. PMID 18409020 DOI: 10.1007/S12253-008-9018-Z |
0.263 |
|
| 2015 |
Nemes K, Csóka M, Nagy N, Márk Á, Váradi Z, Dankó T, Kovács G, Kopper L, Sebestyén A. Expression of Certain Leukemia/Lymphoma Related microRNAs and its Correlation with Prognosis in Childhood Acute Lymphoblastic Leukemia. Pathology Oncology Research : Por. 21: 597-604. PMID 25388103 DOI: 10.1007/S12253-014-9861-Z |
0.26 |
|
| 2010 |
Nemes K, Márk A, Hajdu M, Sticz T, Csorba G, Kopper L, Csóka M, Sebestyén A. 773 MicroRNA expression analysis in human lymphoma/leukemia cells European Journal of Cancer Supplements. 8: 195. DOI: 10.1016/s1359-6349(10)71569-x |
0.26 |
|
| 2007 |
Balogh Z, Reiniger L, Deák L, Bödör C, Csomor J, Szepesi A, Gagyi E, Kopper L, Matolcsy A. IgVH gene mutation status and genomic imbalances in chronic lymphocytic leukaemia with increased prolymphocytes (CLL/PL). Hematological Oncology. 25: 90-5. PMID 17410523 DOI: 10.1002/Hon.812 |
0.258 |
|
| 2006 |
Pap ?, Micsik T, Polg??r B, R??ski K, P??terffy F, Schafer E, Di??falvi K, Holl??sy F, Kopper L, Schwab R, Szekeres-Barth?? J, Pet??k I. PIBF (PROGESTERON INDUCED BLOCKING FACTOR) IS ELEVATED IN PANCREATIC CANCER PATIENTS Pancreas. 33: 488. DOI: 10.1097/00006676-200611000-00175 |
0.257 |
|
| 2005 |
Kopper L, Zalatnai A, Tímár J. Genomics of pancreatic cancer: does it make any improvement in diagnosis, prognosis and therapy? Pathology Oncology Research : Por. 11: 69-73. PMID 15999149 DOI: 10.1007/Bf02893369 |
0.256 |
|
| 2009 |
Kopper L, Tímár J. [Validation study of KRAS mutation in colorectal cancer]. Magyar Onkologia. 53: 361-6. PMID 20071308 DOI: 10.1556/Monkol.53.2009.4.5 |
0.255 |
|
| 1987 |
Kopper L, Nagy P, Bánkfalvi Á. Human lymphoma xenografts in drug screening European Journal of Cancer and Clinical Oncology. 23: 1769-1770. DOI: 10.1016/0277-5379(87)90614-6 |
0.251 |
|
| 2012 |
Kopper L. Denosumab--a powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts. Pathology Oncology Research : Por. 18: 743-7. PMID 22588706 DOI: 10.1007/S12253-012-9538-4 |
0.249 |
|
| 1989 |
Sasvári-Székely M, Spasokukotskaja T, Soóki-Tóth A, Pogany G, Kopper L, Staub M. Deoxycytidine is salvaged not only into DNA but also into phospholipid precursors. II. Ara-C does not inhibit the later process in lymphoid cells. Biochemical and Biophysical Research Communications. 163: 1158-67. PMID 2783114 DOI: 10.1016/0006-291X(89)92342-5 |
0.246 |
|
| 2001 |
Berczi L, Sebestyén A, Fekete B, Tamássy K, Kopper L. IgE-containing cells in gastric mucosa with and without Helicobacter pylori infection. Pathology, Research and Practice. 196: 831-4. PMID 11156324 DOI: 10.1016/S0344-0338(00)80083-7 |
0.24 |
|
| 2005 |
Schwab R, Pinter F, Moldavy J, Papay J, Strausz J, Kopper L, Keri G, Pap A, Petak I, Oreskovich K, Mangel L. Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7736-8. PMID 16234532 DOI: 10.1200/Jco.2005.02.4760 |
0.235 |
|
| 2004 |
Kopper L, Hajdú M. Tumor stem cells. Pathology Oncology Research : Por. 10: 69-73. PMID 15188021 |
0.235 |
|
| 1982 |
Schaff Z, Pohl O, Bencsáth M, Brojnás J, Lapis K, Kopper L, Hollós I. HBsAg-like structures in immunosuppressed mice inoculated with human hepatitis B virus. Virchows Archiv. B, Cell Pathology Including Molecular Pathology. 40: 249-61. PMID 6127839 DOI: 10.1007/Bf02932868 |
0.233 |
|
| 2003 |
Rásó E, Paku S, Kopper L, Tímár J. Trace elements improve survival of DTIC-treated mice with overt liver metastases of Lewis lung carcinoma. Pathology Oncology Research : Por. 9: 96-9. PMID 12858213 DOI: 10.1007/Bf03033751 |
0.232 |
|
| 1985 |
Rajnai J, Kopper L, Lapis K. Subrenal capsule (SRC) assay as a chemotherapeutic tool European Journal of Cancer and Clinical Oncology. 21: 1409. DOI: 10.1016/0277-5379(85)90452-3 |
0.227 |
|
| 2005 |
Moldvay J, Schwab R, Pinter F, Oreskovich K, Petak I, Keri G, Pap A, Strausz J, Kopper L. P-966 Gefitinib treatment in brain metastasis of lung adenocarcinoma with EGFR amplification and mutation (case report) Lung Cancer. 49: S374. DOI: 10.1016/S0169-5002(05)81459-X |
0.223 |
|
| 2007 |
Hajdu M, Sebestyén A, Kopper L. 382 POSTER Interacting effect of TGFb and Notch signaling in B-cell lymphomas European Journal of Cancer Supplements. 5: 79. DOI: 10.1016/S1359-6349(07)70400-7 |
0.222 |
|
| 2003 |
Kopper L. [Apoptosis and tumors]. Magyar Onkologia. 47: 123-31. PMID 14649671 |
0.221 |
|
| 2010 |
Becságh P, Varga K, Szakács O, Kopper L, Orosz Z. High resolution melting curve analysis of DNA sequence alterations of various sizes. Pathology Oncology Research : Por. 16: 421-6. PMID 20490737 DOI: 10.1007/S12253-010-9274-6 |
0.218 |
|
| 1985 |
Kopper L, Lapis K. What's new in macrophage-tumor cell interaction? Pathology, Research and Practice. 179: 652-5. PMID 3895203 DOI: 10.1016/S0344-0338(85)80212-0 |
0.209 |
|
| 1981 |
Timár J, Kopper L, Lapis K. Electronmicroscopical detection of iota-carrageenan as its ruthenium red complex. Histochemistry. 72: 101-6. PMID 6169688 DOI: 10.1007/Bf00496784 |
0.205 |
|
| 2006 |
Micsik T, Polgár B, Schäfer E, Diófalvi K, Rásky K, Péterfy F, Hollósy F, Pap Á, Szekeres-Bartho J, Schwab R, Kopper L, Peták I. The potential tumormarker PIBF is elevated in colorectal and pancreatic cancers Zeitschrift FüR Gastroenterologie. 44. DOI: 10.1055/S-2006-943442 |
0.205 |
|
| 2005 |
Görög D, Regöly-Mérei J, Paku S, Kopper L, Nagy P. Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma. World Journal of Gastroenterology. 11: 5015-8. PMID 16124056 DOI: 10.3748/Wjg.V11.I32.5015 |
0.202 |
|
| 2010 |
Sipeky C, Keri G, Kiss A, Kopper L, Matolcsy A, Timar J, Molnar M, Nagy L, Nemeth G, Petak I, Rasko I, Falus A, Melegh B. Population Pharmacogenomics and Personalized Medicine Research in Hungary: Achievements and Lessons Learned Current Pharmacogenomics and Personalized Medicine. 8: 194-201. DOI: 10.2174/187569210792246344 |
0.199 |
|
| 1997 |
Kopper L, Peták I, Sebestyén A. Molecular genetic basis of cancer development. Annals of the New York Academy of Sciences. 824: 1-7. PMID 9382434 DOI: 10.1111/J.1749-6632.1997.Tb46205.X |
0.197 |
|
| 2005 |
Schwab R, Peták I, Pintér F, Szabó E, Kánya M, Tamási A, Várkondi E, Almási A, Szokolóczi O, Pápay J, Moldvay J, Kéri G, Kopper L. [Epidermal growth factor receptor (EGFR): therapeutic target in the treatment of lung adenocarcinoma]. Orvosi Hetilap. 146: 2335-42. PMID 16370245 |
0.197 |
|
| 1988 |
Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel ME. Evidence for a novel gene associated with low tumor metastatic potential Journal of the National Cancer Institute. 80: 200-204. PMID 3346912 DOI: 10.1093/jnci/80.3.200 |
0.196 |
|
| 2006 |
Kopper L, Hajdú M. [Tumor stem cells--a possible scenario]. Magyar Onkologia. 50: 101-6. PMID 16888672 |
0.194 |
|
| 2005 |
Jánosi J, Sebestyén A, Mikala G, Petö M, Jákó J, Domján G, Németh J, Kis Z, Kopper L, Vályi-Nagy I. [Soluble syndecan-1 levels in different plasma cell dyscrasias]. Orvosi Hetilap. 146: 165-8. PMID 15751511 |
0.188 |
|
| 2011 |
Kopper L, Tímár J. [mTOR complexes -- molecular spiders in molecular networks]. Magyar Onkologia. 55: 287-94. PMID 22128312 |
0.184 |
|
| 2006 |
Tímár J, Kopper L, Bodrogi I. [Molecular pathology and targeted therapy of clear cell renal cancer]. Magyar Onkologia. 50: 309-14. PMID 17216004 |
0.183 |
|
| 2021 |
Sebestyén A, Kopper L, Dankó T, Tímár J. Hypoxia Signaling in Cancer: From Basics to Clinical Practice. Pathology Oncology Research : Por. 27: 1609802. PMID 34257622 DOI: 10.3389/pore.2021.1609802 |
0.179 |
|
| 1985 |
Timar J, Boldog F, Kopper L, Lapis K. Flow cytometric measurements and electron microscopy of cell surface glycosaminoglycans using acridine orange. The Histochemical Journal. 17: 71-9. PMID 3988548 DOI: 10.1007/BF01003404 |
0.176 |
|
| 1980 |
Szende B, Lapis K, Elek G, Suba Z, Kopper L. E-N-trimethyl lysine: a possible aspecific immunestimulant International Journal of Immunopharmacology. 2: 169. DOI: 10.1016/0192-0561(80)90076-4 |
0.173 |
|
| 2000 |
Wong YC, Wang YZ, Lee JSK, Tam NNC, Lee D, Sebestyén A, Tótth Á, Mihalik R, Szakács O, Paku S, Kopper L, Lutsenko SV, Feldman NB, Finakova GV, Gukasova NV, et al. Subject Index Vol. 21, 2000 Tumor Biology. 21: 383-384. DOI: 10.1159/000030145 |
0.17 |
|
| 2000 |
Wong YC, Wang YZ, Lee JSK, Tam NNC, Lee D, Sebestyén A, Tótth Á, Mihalik R, Szakács O, Paku S, Kopper L, Lutsenko SV, Feldman NB, Finakova GV, Gukasova NV, et al. Contents Vol. 21, 2000 Tumor Biology. 21: 385-386. DOI: 10.1159/000030146 |
0.17 |
|
| 1981 |
Kopper L, Lapis K, Hegedüs C. Chemotherapeutic sensitivity of human colorectal tumor xenografts. Oncology. 42-50. PMID 7454200 DOI: 10.1159/000225496 |
0.169 |
|
| 2004 |
Beretta G, Fraschini P, Tedeschi L, Holczinger L, Somfai-Relle S, Institoris E, Gáti É, Turi G, Goldin A, Spreafico F, Weber G, Mechl Z, Malíř A, Mihich E, Arnold W, ... ... Kopper L, et al. Contents, Vol. 37, Supplement 1, 1980 Oncology. 37. DOI: 10.1159/000225491 |
0.168 |
|
| 1990 |
Timár J, Kovalszky I, Paku S, Lapis K, Kopper L. Two human melanoma xenografts with different metastatic capacity and glycosaminoglycan pattern. Journal of Cancer Research and Clinical Oncology. 115: 554-7. PMID 2606930 DOI: 10.1007/Bf00391357 |
0.164 |
|
| 1982 |
Kopper L, Van Hanh T, Lapis K. Experimental model for liver metastasis formation using Lewis lung tumor. Journal of Cancer Research and Clinical Oncology. 103: 31-8. PMID 7076715 DOI: 10.1007/BF00410303 |
0.143 |
|
| 1990 |
Süli-Vargha H, Jeney A, Kopper L, Oláh J, Lapis K, Botyánszki J, Csukás I, Gyövári B, Medzihradszky K. Investigations on the antitumor effect and mutagenicity of alpha-MSH fragments containing melphalan. Cancer Letters. 54: 157-62. PMID 2171755 DOI: 10.1016/0304-3835(90)90038-Y |
0.143 |
|
| 1996 |
Berczi L, Tamássy K, Fekete B, Kopper L. Eosinophils and Mast Cells in Helicobacter Pylori Infected Gastric Mucosa. Pathology Oncology Research : Por. 2: 229-236. PMID 11173609 DOI: 10.1007/Bf02904816 |
0.116 |
|
| 2005 |
Szende B, Paku S, Rácz G, Kopper L. Effect of Fraxiparine and heparin on experimental tumor metastasis in mice. Anticancer Research. 25: 2869-72. PMID 16080539 |
0.116 |
|
| 1981 |
Szabó Z, Dworák O, Kopper L, Lapis K. Effect of combined surgical and chemotherapeutic treatment of Lewis lung carcinoma. Journal of Cancer Research and Clinical Oncology. 97: 161-6. PMID 7462295 DOI: 10.1007/BF00409902 |
0.116 |
|
| 2002 |
Kopper L, Tímár J. [Gene expression profiles in the diagnosis and prognosis of cancer]. Magyar Onkologia. 46: 3-9. PMID 12050676 |
0.115 |
|
| 1981 |
Csányi E, Horváth T, Király E, Lapis K, Kopper L. New type bifunctional nitrosoureido derivatives with cytostatic activity. Oncology. 59-66. PMID 7454201 DOI: 10.1159/000225498 |
0.087 |
|
| 1989 |
Kopper L, Timár J, Jeney A, Lapis K. Glycosaminoglycan (GAG) metabolism as a potential target to prevent metastasis formation. Advances in Experimental Medicine and Biology. 233: 367-75. PMID 3223391 DOI: 10.1007/978-1-4899-5037-6_40 |
0.061 |
|
| 2020 |
Kopper L, Tímár J. 25th Anniversary of Pathology Oncology Research Pathology & Oncology Research. 26: 1-1. DOI: 10.1007/S12253-020-00795-2 |
0.015 |
|
| 2024 |
Tímár J, Ladányi A, Sebestyén A, Kopper L. Editorial: Pathology and Oncology Research: addressing publication ethics issues. Pathology Oncology Research : Por. 30: 1611691. PMID 38420138 DOI: 10.3389/pore.2024.1611691 |
0.01 |
|
| 2003 |
Kopper L, Tĺmár J. Retraction of publication. Pathology Oncology Research : Por. 9: 165. PMID 14689962 |
0.01 |
|
| Hide low-probability matches. |